Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Elyse Lower

Medical Oncology Cincinnati, OH Medical Doctor

NPI 1447244843 CMS profile 689333

234 Goodman St, Cincinnati, OH 45219

Open in the dashboard

General payments

$312,378

256 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$47,725 paid to institutions, not to them · program years 2019–2025

Through program year 2023, Elyse Lower of Cincinnati, OH is reported in the CMS Open Payments database as having received $312,378 across 256 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $47,725 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $24,473 16
2022 General $97,813 66
2021 General $49,601 63
2020 General $51,331 47
2019 General $89,161 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elyse Lower
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Elyse Lower were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Elyse Lower Medical Oncology median Middle half National median
2019 $89,161 $968 $140–$6,658 $163
2020 $51,331 $747 $102–$5,891 $114
2021 $49,601 $430 $50–$4,098 $132
2022 $97,813 $812 $127–$4,907 $149
2023 $24,473 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Gilead Sciences, Inc. $87,282 46 payments
  2. AstraZeneca Pharmaceuticals LP $60,298 37 payments
  3. Novartis Pharmaceuticals Corporation $55,107 39 payments
  4. Seattle Genetics, Inc. $49,278 24 payments
  5. Daiichi Sankyo Inc. $32,067 20 payments
  6. Puma Biotechnology, Inc. $14,697 18 payments
  7. Immunomedics, Inc. $5,360 3 payments
  8. Gen-Probe Sales & Service, Inc. $4,152 13 payments
  9. Eisai Inc. $1,745 2 payments
  10. Hologic, LLC $1,213 4 payments
  11. Other $1,179 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $235,290 60 payments
  2. Travel and Lodging $44,242 79 payments
  3. Consulting Fee $27,134 16 payments
  4. Food and Beverage $5,701 100 payments
  5. Education $12 1 payment
Products named General payments · program years 2019–2023
  1. Trodelvy Onc $86,630 43 payments
  2. KISQALI $53,442 36 payments
  3. TUKYSA $49,278 24 payments
  4. LYNPARZA $36,128 24 payments
  5. ENHERTU $32,067 20 payments
  6. PIQRAY $27,360 22 payments
  7. NERLYNX $14,697 18 payments
  8. TRODELVY Oncology $5,360 3 payments
  9. BTX $4,221 14 payments
  10. Halaven $1,745 2 payments
  11. Other $3,083 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record